ORIGINAL RESEARCH article
Front. Oncol.
Sec. Pediatric Oncology
This article is part of the Research TopicIntegrative Approaches in Neuroblastoma Research: Pathogenesis and Strategies for Diagnosis and PrognosisView all articles
The Dynamic Systemic Immuno-Inflammatory Index: A Novel Predictor of Neoadjuvant Chemotherapy Response and Outcome in High-Risk Pediatric Neuroblastoma
Provisionally accepted
- 1Hebei Provincial Children's Hospital, Shijiazhuang, China
- 2Hebei Provincial People's Hospital, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: High-risk neuroblastoma (HR-NB) has a high mortality rate and a long-term survival rate below 50%. Neoadjuvant chemotherapy (NAC) is essential for HR-NB treatment. However, real-time treatment response biomarkers are lacking. The Systemic Immune-Inflammation Index (SII) shows promise as a prognostic tool for various malignancies. This study explored the relationship between dynamic SII changes during NAC and treatment responses and prognosis in HR-NB. Methods: This retrospective study analyzed 50 HR-NB patients' clinical data from January 2013 to November 2024. Peripheral blood samples were collected before and after each cycle of neoadjuvant chemotherapy (NAC) to calculate SII values. Results: Significant differences in SII changes were found among treatment response groups (P < 0.05). Spearman analysis showed a strong positive correlation between ΔSII and tumor diameter change rate (r = 0.606, P < 0.001). Regression analyses indicated ΔSII was an independent predictor of tumor diameter change (β = 0.07, 95% CI: 0.05-0.10, P < 0.001) and chemosensitivity (OR = 0.00, 95% CI: 0.00-0.03, P = 0.010). ΔSII was also an independent prognostic factor for EFS and OS (HR = 1.35 and 1.41, P < 0.05) with high predictive accuracy (AUC: 0.766-0.932). Conclusion: Dynamic SII changes during NAC are significantly linked to treatment response and prognosis in HR-NB, offering a new perspective for precision treatment and prognosis evaluation.
Keywords: High-risk neuroblastoma, Neoadjuvant chemotherapy, systemic immune-inflammation index, Dynamic changes, overall survival
Received: 22 Jul 2025; Accepted: 27 Oct 2025.
Copyright: © 2025 Zhang, Wang, Niu, Zhang and Geng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jianlei Geng, genglei653@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.